Menu
Recruiting NCT00064870

Alzheimer's Disease Genetics Study

Observational Alzheimer Disease Late Onset Alzheimer Disease Dementia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Alzheimer Disease, Late Onset Alzheimer Disease, Dementia. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)

Overview

The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed with AD or dementia.

Detailed description

The purpose of the Alzheimer's Disease Genetics Study is to help identify the genes that may be responsible for causing Alzheimer's Disease (AD) by collecting genetic material from families with multiple members diagnosed with AD. Qualifying families will have two living blood-related individuals who have been diagnosed with or are showing symptoms of AD or dementia. Local study sites are located all over the United States, and arrangements may be made for eligible families who do not live near a participating site. The biological samples and data from these families will be made available to qualified researchers, who must sign a Materials Transfer Agreement (MTA) in order to protect the privacy rights of study participants before receiving samples and data.

Primary outcome measures

  • Distribute biological specimens to qualified investigators for use in their research studies. [Time frame: Contact investigators annually for an update on progress and publication status.]

Eligibility criteria

Inclusion criteria

  • Two living family members diagnosed with AD or other dementia with any age of onset
  • Biological samples available
  • Fresh blood, or
  • Immortalized lymphoblastic cell lines, or
  • 3-5 grams of frozen cerebral cortex; fixed samples are not accepted

Please note: this study does not include genetic counseling; because no personal identifying information such as name or date of birth is attached to samples, results of individual tests are not available to participants or family members.

Exclusion criteria

  • Does not meet inclusion criteria
  • Member of a family that was included in the National Institute of Mental Health AD Genetics Sib Pair collection

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • Participants are being recruited from all over the United States — Nationwide

Identifiers

NCT: NCT00064870 · IA0042 · U24AG021886 · NIH grant U24 AG21886

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗